Pertuzumab

Pertuzumab Brand Name– PERJETA

What is Pertuzumab

Pertuzumab is a humanized recombinant monoclonal antibody that blocks ligand-dependent heterodimerization of human epidermal growth factor receptor-2 (HER2) and other epidermal growth factor receptors resulting in the inhibition of intracellular signaling pathways and eventually cell growth arrest and apoptosis.

Pertuzumab also demonstrates antibody-dependent cell-mediated cytotoxicity.

It was FDA-approved in 2012 for the first-line treatment of HER2-positive metastatic breast cancer in combination with trastuzumab and docetaxel based on a significant improvement in progression-free survival compared with placebo.

Since then, the indication has been expanded to include neoadjuvant treatment of HER2-positive, locally advanced, inflammatory, or early stage breast cancer in combination with trastuzumab and docetaxel as part of a complete regimen for early breast cancer, as well as for the adjuvant treatment of HER2-positive early breast cancer at high risk of recurrence.

Indications

• breast cancer

For the treatment of HER2-positive breast cancer

Side Effects

1. abdominal pain
2. abdominal pain
3. alopecia
4. alopecia
5. anaphylactoid reactions
6. anemia
7. anemia
8. angioedema
9. anorexia
10. anorexia
11. antibody formation
12. arthralgia
13. arthralgia
14. asthenia
15. asthenia
16. back pain
17. bone pain
18. bone pain
19. chills
20. constipation
21. constipation
22. cough
23. cough
24. cytokine release syndrome
25. diarrhea
26. diarrhea
27. dizziness
28. dizziness
29. dysgeusia
30. dysgeusia
31. dyspepsia
32. dyspepsia
33. dyspnea
34. dyspnea
35. elevated hepatic enzymes
36. elevated hepatic enzymes
37. epistaxis
38. epistaxis
39. fatigue
40. fatigue
41. fetal death
42. fever
43. fever
44. gastroesophageal reflux
45. headache
46. headache
47. heart failure
48. hot flashes
49. hot flashes
50. hyperphosphatemia
51. hyperuricemia
52. hypokalemia
53. infection
54. infection
55. infusion-related reactions
56. infusion-related reactions
57. insomnia
58. insomnia
59. lacrimation
60. leukopenia
61. leukopenia
62. myalgia
63. myalgia
64. nausea
65. nausea
66. neutropenia
67. neutropenia
68. palmar-plantar erythrodysesthesia (hand and foot syndrome)
69. palmar-plantar erythrodysesthesia (hand and foot syndrome)
70. paresthesias
71. paresthesias
72. peripheral edema
73. peripheral edema
74. peripheral neuropathy
75. peripheral neuropathy
76. pharyngitis
77. pharyngitis
78. pleural effusion
79. pruritus
80. pruritus
81. radiation recall reaction
82. radiation recall reaction
83. rash
84. rash
85. renal failure (unspecified)
86. stomatitis
87. stomatitis
88. teratogenesis
89. thrombocytopenia
90. thrombocytopenia
91. tumor lysis syndrome (TLS)
92. vomiting
93. vomiting
94. xerosis
95. xerosis

Monitoring Parameters

• ejection fraction
• pregnancy testing

Contraindications

• breast-feeding
• cardiac arrhythmias
• cardiac disease
• contraception requirements
• heart failure
• hypertension
• infusion-related reactions
• intrauterine fetal death
• myocardial infarction
• pregnancy
• pregnancy testing
• radiation therapy
• reproductive risk
• tumor lysis syndrome (TLS)
• ventricular dysfunction

Interactions

• Clozapine
• Palifermin
• Penicillamine
• Tuberculin Purified Protein Derivative, PPD